Laura Chico
Stock Analyst at Wedbush
(2.21)
# 2,651
Out of 4,711 analysts
198
Total ratings
40.15%
Success rate
-4.16%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Reiterates: Outperform | $148 | $135.42 | +9.29% | 8 | Dec 16, 2024 | |
| SLDB Solid Biosciences | Initiates: Outperform | $16 | $4.16 | +284.62% | 1 | Dec 13, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $44 → $45 | $30.78 | +46.20% | 9 | Nov 8, 2024 | |
| VIGL Vigil Neuroscience | Maintains: Outperform | $23 → $24 | $1.70 | +1,311.76% | 8 | Nov 8, 2024 | |
| PEPG PepGen | Maintains: Outperform | $19 → $12 | $3.63 | +230.58% | 9 | Nov 8, 2024 | |
| VERA Vera Therapeutics | Maintains: Neutral | $30 → $38 | $42.60 | -10.80% | 7 | Nov 8, 2024 | |
| ANRO Alto Neuroscience | Downgrades: Neutral | $29 → $4 | $3.89 | +2.83% | 3 | Oct 23, 2024 | |
| SAGE Sage Therapeutics | Maintains: Neutral | $9 → $8 | $5.61 | +42.60% | 8 | Oct 9, 2024 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $17 → $25 | $17.18 | +45.52% | 9 | Oct 9, 2024 | |
| LRMR Larimar Therapeutics | Initiates: Outperform | $22 | $4.01 | +448.63% | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $210 → $205 | $146.47 | +39.96% | 16 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $48 | $76.52 | -37.27% | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $9.56 | +130.13% | 8 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $4 | $0.84 | +376.19% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $41 | $33.21 | +23.46% | 13 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $49 | $38.63 | +26.84% | 8 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $36 | $23.80 | +51.26% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $5.75 | +21.74% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $21.45 | +21.21% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $43 → $46 | $44.22 | +4.03% | 11 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $4.82 | +128.22% | 13 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $19.03 | +120.70% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $17 | $11.68 | +45.55% | 6 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $41 | $2.53 | +1,520.55% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $31 | $19.57 | +58.41% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.95 | +1,057.89% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $1.00 | +700.72% | 1 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $6.25 | -20.00% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $65.66 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $1.85 | +170.27% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $36.26 | +309.54% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $13.00 | +5,438.46% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $23.22 | +1,105.86% | 1 | Apr 21, 2017 |
Neurocrine Biosciences
Dec 16, 2024
Reiterates: Outperform
Price Target: $148
Current: $135.42
Upside: +9.29%
Solid Biosciences
Dec 13, 2024
Initiates: Outperform
Price Target: $16
Current: $4.16
Upside: +284.62%
Edgewise Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $44 → $45
Current: $30.78
Upside: +46.20%
Vigil Neuroscience
Nov 8, 2024
Maintains: Outperform
Price Target: $23 → $24
Current: $1.70
Upside: +1,311.76%
PepGen
Nov 8, 2024
Maintains: Outperform
Price Target: $19 → $12
Current: $3.63
Upside: +230.58%
Vera Therapeutics
Nov 8, 2024
Maintains: Neutral
Price Target: $30 → $38
Current: $42.60
Upside: -10.80%
Alto Neuroscience
Oct 23, 2024
Downgrades: Neutral
Price Target: $29 → $4
Current: $3.89
Upside: +2.83%
Sage Therapeutics
Oct 9, 2024
Maintains: Neutral
Price Target: $9 → $8
Current: $5.61
Upside: +42.60%
Travere Therapeutics
Oct 9, 2024
Maintains: Outperform
Price Target: $17 → $25
Current: $17.18
Upside: +45.52%
Larimar Therapeutics
Oct 3, 2024
Initiates: Outperform
Price Target: $22
Current: $4.01
Upside: +448.63%
Sep 23, 2024
Maintains: Neutral
Price Target: $210 → $205
Current: $146.47
Upside: +39.96%
Aug 14, 2024
Maintains: Neutral
Price Target: $40 → $48
Current: $76.52
Upside: -37.27%
Aug 13, 2024
Reiterates: Outperform
Price Target: $22
Current: $9.56
Upside: +130.13%
Aug 13, 2024
Reiterates: Outperform
Price Target: $4
Current: $0.84
Upside: +376.19%
Aug 9, 2024
Maintains: Neutral
Price Target: $38 → $41
Current: $33.21
Upside: +23.46%
Aug 9, 2024
Maintains: Outperform
Price Target: $50 → $49
Current: $38.63
Upside: +26.84%
Aug 9, 2024
Maintains: Outperform
Price Target: $38 → $36
Current: $23.80
Upside: +51.26%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $5.75
Upside: +21.74%
Aug 2, 2024
Maintains: Outperform
Price Target: $30 → $26
Current: $21.45
Upside: +21.21%
Aug 2, 2024
Maintains: Neutral
Price Target: $43 → $46
Current: $44.22
Upside: +4.03%
Aug 2, 2024
Reiterates: Outperform
Price Target: $11
Current: $4.82
Upside: +128.22%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $19.03
Upside: +120.70%
Jul 11, 2024
Reiterates: Outperform
Price Target: $17
Current: $11.68
Upside: +45.55%
Jun 6, 2024
Reiterates: Outperform
Price Target: $41
Current: $2.53
Upside: +1,520.55%
May 9, 2024
Maintains: Outperform
Price Target: $35 → $31
Current: $19.57
Upside: +58.41%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.95
Upside: +1,057.89%
Apr 5, 2024
Initiates: Outperform
Price Target: $8
Current: $1.00
Upside: +700.72%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $6.25
Upside: -20.00%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $65.66
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $1.85
Upside: +170.27%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $36.26
Upside: +309.54%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $13.00
Upside: +5,438.46%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $23.22
Upside: +1,105.86%